Clinical Trial Results
临床试验结果

 

国际期刊《肿瘤学家》杂志旗下Clinical Trial Results (CTR)平台以共享成果,助力科研为使命。基于每个临床试验,不论其最终结果如何,都会给研究者带来获益的信念,《肿瘤学家》杂志致力于领衔建立共享平台以发布所有临床试验结果。
我们邀请您探索本期精选的CTR,共享成果,助力科研。从新药的I期可行性临床试验到对联合治疗方案的有效性和耐受性进行研究的大样本II期临床试验,CTR对不同的治疗方案提供有益的见解,这些方案有些成功了,有些失败了,但他们都对未来研究有所裨益。

 

您可通过CTR平台http://clinicaltrialresults.theoncologist.com 快速发布您自己的CTR!

Clinical Trial Results (CTR) from The Oncologist promotes the mission of sharing results to speed discoveries. Motivated by the belief that every trial, regardless of outcome, can have a benefit to the research community, The Oncologist has taken a leadership role in providing a forum for the publication of all trials.
We invite you to explore this selection of Clinical Trial Results published in support of this mission. From phase I feasibility studies of novel agents to larger-scale phase II trials studying efficacy and tolerability of combination therapies, CTR offers helpful insights into a variety of therapeutic approaches, some successful, others not, but all of which can inform future research.

Submit your own CTR at http://clinicaltrialresults.theoncologist.com.


Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
Hendrik‐Tobias Arkenau, Juan Martin‐Liberal, Emiliano Calvo, Nicolas Penel, Matthew G. Krebs, Roy S. Herbst, Richard A. Walgren, Ryan C. Widau, Gu Mi, Jin Jin, David Ferry, Ian Chau
The Oncologist first published on May 16, 2018; doi:10.1634/theoncologist.2017-0657

Phase II Study of Irinotecan Plus Panitumumab as Second‐Line Therapy for Patients with Advanced Esophageal Adenocarcinoma
Harry Yoon, Lilit Karapetyan, Anita Choudhary, Ramla Kosozi, Gurvinder Singh Bali, Ali H. Zaidi, Ajlan Atasoy, Arlene A. Forastiere, Michael K. Gibson
The Oncologist first published on May 16, 2018; doi:10.1634/theoncologist.2017-0657

NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer
Vanesa Gregorc, Raffaele Cavina, Sivia Novello, Francesco Grossi, Chiara Lazzari, Enrica Capelletto, Carlo Genova, Giulia Salini, Antonio Lambiase, Armando Santoro
The Oncologist first published on August 3, 2018; doi:10.1634/theoncologist.2018-0292

NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer
Vanesa Gregorc, Raffaele Cavina, Sivia Novello, Francesco Grossi, Chiara Lazzari, Enrica Capelletto, Carlo Genova, Giulia Salini, Antonio Lambiase, Armando Santoro
The Oncologist first published on August 3, 2018; doi:10.1634/theoncologist.2018-0292

Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Pilar García‐Alfonso, Manuel Benavides, Esther Falcó, Andrés Muñoz, Auxiliadora Gómez, Javier Sastre, Fernando Rivera, Clara Montagut, Mercedes Salgado, Amelia López‐Ladrón, Rafael López, Inmaculada Ruiz de Mena, Gema Durán, Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD)
The Oncologist first published on August 17, 2018; doi:10.1634/theoncologist.2018-0316

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance)
William J. Maples, Val J. Lowe, Edward T. Creagan, Lori A. Erickson, and Svetomir Markovic
The Oncologist 2018; 23:887-e94; first published on April 17, 2018; doi:10.1634/theoncologist.2018-0100

A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy
Angela C. Hirbe, Jack Jennings, Nael Saad, Joseph D. Giardina, Yu Tao, Jingqin Luo, Shellie Berry, Jacqui Toeniskoetter, and Brian A. Van Tine
The Oncologist 2018; 23:760-e76; first published on February 27, 2018; doi:10.1634/theoncologist.2017-0536

Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin
Elizabeth Fox, Kristin Levin, Yan Zhu, Blair Segers, Naomi Balamuth, Richard Womer, Rochelle Bagatell, and Frank Balis
The Oncologist 2018; 23:762-e79; first published on February 14, 2018; doi:10.1634/theoncologist.2018-0037

Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin
Elizabeth Fox, Kristin Levin, Yan Zhu, Blair Segers, Naomi Balamuth, Richard Womer, Rochelle Bagatell, and Frank Balis
The Oncologist 2018; 23:762-e79; first published on February 14, 2018; doi:10.1634/theoncologist.2018-0037

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
Vanessa Trieu, Harlan Pinto, Jonathan W. Riess, Ruth Lira, Richard Luciano, Jessie Coty, Derek Boothroyd, and A. Dimitrios Colevas
The Oncologist 2018; 23:764-e86; first published on March 14, 2018; doi:10.1634/theoncologist.2017-0618

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors
Ramon Salazar, Rocio Garcia-Carbonero, Steven K. Libutti, Andrew E. Hendifar, Ana Custodio, Rosine Guimbaud, Catherine Lombard-Bohas, Sergio Ricci, Heinz-Josef Klümpen, Jaume Capdevila, Nicholas Reed, Annemiek Walenkamp, Enrique Grande, Sufiya Safina, Tim Meyer, Oliver Kong, Herve Salomon, Ranjana Tavorath, and James C. Yao
The Oncologist 2018; 23:766-e90; first published on December 14, 2017; doi:10.1634/theoncologist.2017-0144

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer
Joachim von Pawel, David R. Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, and Martin Reck
The Oncologist 2018; 23:654-e58; first published on February 7, 2018; doi:10.1634/theoncologist.2017-0690

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer
Xiao X. Wei, Adam P. Siegel, Rahul Aggarwal, Amy M. Lin, Terence W. Friedlander, Lawrence Fong, Won Kim, Mirela Louttit, Emily Chang, Li Zhang, and Charles J. Ryan
The Oncologist 2018; 23:656-e64; first published on February 27, 2018; doi:10.1634/theoncologist.2017-0624

A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony Tolcher, Keith Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas Witzig, Thomas Habermann, Andrea Bullock, Edwin Rock, Agnes Elekes, Chester Lin, Dusan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, and Gregory M. Cote
The Oncologist 2018; 23:658-e72; first published on March 6, 2018; doi:10.1634/theoncologist.2017-0325

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier L. Chinot, Maryline Barrie, Luc Taillandier, Patrick Beauchesne, Isabelle Catry-Thomas, Jérôme Barrière, Jean-Sebastien Guillamo, Michel Fabbro, Didier Frappaz, Alexandra Benouaich-Amiel, Emilie Le Rhun, Chantal Campello, Isabelle Tennevet, Francois Ghiringhelli, Marie-Laure Tanguy, Karima Mokhtari, Jérôme Honnorat, and Jean-Yves Delattre
The Oncologist 2018; 23:524-e44; first published on February 22, 2018; doi:10.1634/theoncologist.2017-0689

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
William N. William, Jr., Anne S. Tsao, Lei Feng, Lawrence E. Ginsberg, J. Jack Lee, Merrill S. Kies, Bonnie S. Glisson, and Edward S. Kim
The Oncologist 2018; 23:526-e49; first published on January 25, 2018; doi:10.1634/theoncologist.2017-0661

A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma
Francine Marie Foss, and Terri Parker
The Oncologist 2018; 23:397-e30; first published on February 7, 2018; doi:10.1634/theoncologist.2017-0658

Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned
Justin de Brabander, Ferry A.L.M. Eskens, Susanne E. Korsse, Evelien Dekker, Pieter Dewint, Monique E. van Leerdam, Susanne van Eeden, and Heinz-Josef Klümpen
The Oncologist 2018; 23:399-e33; first published on January 25, 2018; doi:10.1634/theoncologist.2017-0682

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Gerald Edelman, Jordi Rodon, Joanne Lager, Christelle Castell, Jason Jiang, Eliezer M. Van Allen, Nikhil Wagle, Neal I. Lindeman, Lynette M. Sholl, and Geoffrey I. Shapiro
The Oncologist 2018; 23:401-e38; first published on March 28, 2018; doi:10.1634/theoncologist.2017-0691

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater
Pat Gulhati, Kanwal Raghav, Rachna Shroff, Gauri Varadhachary, Milind Javle, Wei Qiao, Huamin Wang, Jeffrey Morris, Robert Wolff, and Michael J. Overman
The Oncologist 2018; 23:277-e26; first published on December 19, 2017; doi:10.1634/theoncologist.2017-0568

Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
Emilio P. Araujo-Mino, Yehuda Z. Patt, Cristina Murray-Krezan, Joshua A. Hanson, Pranshu Bansal, Ben J. Liem, Ashwani Rajput, M. Houman Fekrazad, Glenory Heywood, and Fa Chyi Lee
The Oncologist 2018; 23:2-e5; first published on November 20, 2017; doi:10.1634/theoncologist.2017-0474

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study
Liwen Xiong, Rong Li, Jiayuan Sun, Yuqing Lou, Weiyan Zhang, Hao Bai, Huiming Wang, Jie Shen, Bo Jing, Chunlei Shi, Hua Zhong, Aiqin Gu, Liyan Jiang, Jianxing Shi, Wentao Fang, Heng Zhao, Jie Zhang, Junyuan Wang, Junyi Ye, Baohui Han
The Oncologist first published on August 29, 2018; doi:10.1634/theoncologist.2018-0120

 

Previous Collections


2017 Clinical Trial Results